Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Dec 6, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Transperineal Laser Ablation (TPLA) for men with localized prostate cancer. TPLA is a minimally invasive procedure, which means it involves less cutting and might help preserve important functions like bladder control and sexual function compared to traditional treatments. The aim of this study is to gather information about how safe and effective TPLA is, as well as to learn about the overall outcomes for patients who have undergone this treatment.

To participate in this trial, men must be diagnosed with localized prostate cancer and have received TPLA as their treatment. They should be between the ages of 65 and 74. Participants will be part of a registry that collects data on their experiences and outcomes after the treatment. This could help improve our understanding of how TPLA works and provide important information for future patients. If you or a loved one meet these criteria, participating could help contribute to the knowledge about this promising treatment option.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed
• Exclusion Criteria:
• • Age \< 18 years